Korea BNC Discusses Large-Scale Production and Supply Plan for Antroquinonol with Golden Biotech Co.

[Asia Economy Reporter Hyunseok Yoo] Korea BNC announced on the 6th that it is having in-depth discussions with Taiwan's Golden Biotech regarding the mass production and production optimization plans of Antroquinonol, a COVID-19 treatment candidate drug currently in Phase 2 clinical trials approved by the US FDA.

Assuming that after successfully completing Phase 2 clinical trials in the US and other countries, and after applying for and receiving emergency use authorization from the US FDA, approvals and authorizations will be granted by each country, they are envisioning a scenario to supply the necessary drugs to patients with mild to moderate COVID-19 infections in each country. The two companies are closely consulting on the optimal mass production and supply methods.

The production method of Antroquinonol involves fermentation, extraction, and separation of mushroom extracts, which has limitations for mass production. To improve this, they have decided to proactively proceed with synthesizing Antroquinonol for production. Currently, the process for producing raw materials via synthesis has been completed, and comparative tests with raw materials produced by the existing fermentation and extraction method have confirmed physicochemical equivalence.

Considering the current production scale, the supply of synthetic raw materials to Korea, Russia, Turkey, and Ukraine is sufficient, and it is understood that the production of finished pharmaceuticals using these raw materials at Korea BNC will not be hindered. Considering the current number of COVID-19 patients and the expected number of patients to be treated, annual sales are estimated to exceed several hundred billion won.

If the therapeutic efficacy and safety of Antroquinonol are confirmed through clinical trial results and emergency use authorization is granted by the US FDA, demand for the treatment will surge, leading to an increase in production and supply volume and a rapid rise in sales.

Korea BNC established and completed a pharmaceutical GMP production facility in Sejong City last November. They are currently preparing to apply for GMP conformity evaluation. They have planned to apply for GMP certification approval this year and to obtain it within a short period.

They expect that the approval of Antroquinonol, mass synthetic raw material production, and supply of finished pharmaceuticals will be a crucial key to treating many patients affected by the ongoing spread of COVID-19.

This content was produced with the assistance of AI translation services.